These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2326771)

  • 41. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects.
    Chiabrando C; Rivoltella L; Martelli L; Valzacchi S; Fanelli R
    Biochim Biophys Acta; 1992 Feb; 1133(3):247-54. PubMed ID: 1737057
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes of plasma levels of 6-keto-PGF1 alpha and TXB2 in rats during septic and endotoxic shock.
    Tao YP; Chen HC; Xiao DM; Wang F
    Proc Chin Acad Med Sci Peking Union Med Coll; 1987; 2(1):37-40. PubMed ID: 3432249
    [No Abstract]   [Full Text] [Related]  

  • 43. [Effect of dazoxiben on cerebrovascular resistance in rabbits].
    Rui YC; Sun DX; Long K
    Zhongguo Yao Li Xue Bao; 1989 Jul; 10(4):342-5. PubMed ID: 2624120
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Irreversible inhibition of thromboxane (TX) A2 synthesis by Y-20811, a selective TX synthetase inhibitor.
    Mikashima H; Ochi H; Muramoto Y; Hirotsu K; Arima N
    Biochem Pharmacol; 1992 Jan; 43(2):295-9. PubMed ID: 1739418
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of activated platelets in endotoxin-induced DIC in rats.
    Ito T; Asai F; Oshima T; Kobayashi S
    Thromb Res; 1990 Aug; 59(4):735-47. PubMed ID: 2080492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protective effect of a novel thromboxane synthetase inhibitor, CV-4151, on myocardial damage due to coronary occlusion and reperfusion in the hearts of anesthetized dogs.
    Imamoto T; Terashita Z; Tanabe M; Nishikawa K; Hirata M
    J Cardiovasc Pharmacol; 1986; 8(4):832-9. PubMed ID: 2427826
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetic and pharmacodynamic profiles of CS-518, a selective, long-lasting thromboxane synthase inhibitor, after single and multiple oral administration to healthy volunteers.
    Uematsu T; Nagashima S; Inaba H; Mizuno A; Kosuge K; Nakashima M
    J Clin Pharmacol; 1994 Jan; 34(1):41-7. PubMed ID: 8132850
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective effects of G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, in splanchnic artery occlusion shock.
    Squadrito F; Altavilla D; Zingarelli B; Ioculano MP; Campo GM; Calapai G; Saitta A; Urna G; Sardella A; Spignoli G
    J Cardiovasc Pharmacol; 1992 Jan; 19(1):115-9. PubMed ID: 1375677
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Thromboxane, prostaglandin I2 (epoprostenol), and the hemodynamic changes in equine endotoxin shock.
    Bottoms GD; Templeton CB; Fessler JF; Johnson MA; Roesel OF; Ewert KM; Adams SB
    Am J Vet Res; 1982 Jun; 43(6):999-1002. PubMed ID: 7049018
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2 and 6-keto-prostaglandin F1 alpha levels and platelet aggregation.
    Yui Y; Hattori R; Takatsu Y; Nakajima H; Wakabayashi A; Kawai C; Kayama N; Hiraku S; Inagawa T; Tsubojima M
    Circulation; 1984 Oct; 70(4):599-605. PubMed ID: 6434196
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis--effect of a thromboxane synthase inhibitor.
    Carter AJ; Bevan JA; Hanley SP; Morgan WE; Turner DR
    Thromb Haemost; 1984 Apr; 51(2):257-60. PubMed ID: 6377567
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Thromboxane synthetase inhibitors in septic shock.
    Short BL; Gardiner WM; Mishik AN; Ramwell PW; Walker D; Fletcher JR
    Adv Shock Res; 1983; 10():143-8. PubMed ID: 6683924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Abnormal prostanoid metabolism in lupus nephritis and the effects of a thromboxane A2 synthetase inhibitor, DP-1904.
    Yoshida T; Ichikawa Y; Tojo T; Homma M
    Lupus; 1996 Apr; 5(2):129-38. PubMed ID: 8743126
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J; Mehta P; Lawson DL; Ostrowski N; Brigmon L
    J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficiency of prostacyclin in rabbit endotoxin shock.
    Ditter H; Röttger P; Voss R; Matthias FR
    Prog Clin Biol Res; 1987; 236A():369-76. PubMed ID: 3303046
    [No Abstract]   [Full Text] [Related]  

  • 56. Prostaglandin synthetase inhibition in group B streptococcal shock: hematologic and hemodynamic effects.
    Peevy KJ; Panus P; Longenecker GL; Chartrand SA; Wiseman HJ; Boerth RC; Olson RD
    Pediatr Res; 1986 Sep; 20(9):864-6. PubMed ID: 3092176
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In vivo measurement of thromboxane B2 and 6-keto-prostaglandin F1 alpha in humans in response to a standardized vascular injury and the influence of aspirin.
    Gerrard JM; Taback S; Singhroy S; Docherty JC; Kostolansky I; McNicol A; Kobrinsky NL; McKenzie JK; Rowe R
    Circulation; 1989 Jan; 79(1):29-38. PubMed ID: 2910545
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pathophysiological mechanisms of sudden death induced by platelet activating factor.
    Lefer AM; Müller HF; Smith JB
    Br J Pharmacol; 1984 Sep; 83(1):125-30. PubMed ID: 6435705
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antithrombotic activity of garlic: its inhibition of the synthesis of thromboxane-B2 during infusion of arachidonic acid and collagen in rabbits.
    Ali M; Thomson M; Alnaqeeb MA; al-Hassan JM; Khater SH; Gomes SA
    Prostaglandins Leukot Essent Fatty Acids; 1990 Oct; 41(2):95-9. PubMed ID: 2274570
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers.
    Uematsu T; Kosuge K; Umemura K; Nakano M; Terakawa M; Nakashima M
    J Pharm Pharmacol; 1996 Apr; 48(4):380-5. PubMed ID: 8794987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.